[Effect of pamidronate infusion time on renal function in patients with multiple myeloma].
BACKGROUND
Administration of biphosphonates in patients with renal failure requires a dosage adjustment.


OBJECTIVE
Analyse renal function evolution in multiple myeloma patients after reducing infusion time for 90 mg pamidronate by 2 h.


METHODS
In 2007, a retrospective study was carried out on all patients who presented multiple myeloma and bone metastasis treated with pamidronate administered every 4 h. Following a review of the literature, a protocol for administering pamidronate every 2 h was created in partnership with Haematology, and a specific dose reduction framework was established for patients with baseline renal failure. Additionally, a prospective follow-up study of those patients' renal function was completed to analyse its evolution after the change in infusion time.


RESULTS
A total of six patients received 90 mg pamidronate every 4 h. 33.32% of the patients (2/6) presented baseline renal insufficiency, and therefore needed to have the pamidronate dose adjusted according to the new protocol. Subsequently, all of them received the treatment every 2 h, and one patient (16.6%) experienced altered renal function after two treatment cycles.


CONCLUSIONS
Reducing administration time for pamidronate from four to 2 h did not lead to significant variations in patients' renal function. This therapeutic practice can improve patients' quality of life by shortening their hospital stay without aggravating their renal function.
Sierra
F
F
Servicio de Farmacia, Area de Gestión Sanitaria Norte de Almería, Huércal-Overa, Almería, Spain. currosg@hotmail.com
Román
E
E
Barreda
C
C
Moleón
M
M
Pastor
J
J
Navarro
A
A
D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000494:pharmacology*; D004164:Diphosphonates / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D008297:Male; D009101:Multiple Myeloma / Q000503:physiopathology; D000077268:Pamidronate; D012189:Retrospective Studies; D013997:Time Factors
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000077268:Pamidronate